Nicolas Serandour

Nicolas Serandour currently serves as the President of Neurinnov, leading strategic direction, funding strategies, and commercial expansion focused on rehabilitation technologies for tetraplegic patients since January 2024. Prior to this role, Nicolas held the position of Chief Executive Officer at Advanced Oncotherapy plc from 2014 to 2024, where significant advancements were made in proton therapy technology, and over £235 million was raised through innovative financing models and strategic partnerships. Nicolas's earlier experience includes serving as Head of Healthcare Europe at Lazard, where high-impact M&A transactions were advised, and roles at Lehman Brothers as Executive Director of Healthcare Investment Banking and JPMorgan Chase & Co. as Associate in Healthcare Investment Banking, facilitating critical healthcare transactions. Academic qualifications include a degree from ESSEC Business School and a DESS 203 in Risk Management from Université Paris Dauphine - PSL.